BioBrief covers the key biotech and pharma developments from Thursday, April 30, 2026. Axsome secured an FDA approval in Alzheimer’s agitation, AstraZeneca received a split advisory committee outcome across prostate and breast cancer, and uniQure advanced its Huntington’s gene therapy toward a UK filing.

1. Axsome / Auvelity
   • Mechanism: NMDA receptor antagonism and sigma-1 receptor activity via dextromethorphan-bupropion
   • Indication: Agitation associated with Alzheimer’s dementia
   • Stage: FDA approval
   • Key result: ADVANCE-1 showed a 14.9-point agitation score improvement versus 11.6 on placebo at week five
   • Why it matters: Auvelity becomes the first approved non-antipsychotic for this use, with a June US launch expected
2. AstraZeneca / Truqap and camizestrant ...